Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antineoplaston A10 and AS2-1 in Metastatic Prostate Cancer
NCT00003533Phase 2Terminated
- Sponsor
- Burzynski Research Institute
- Start
- Feb 1996
- Primary completion
- Dec 1999
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of antineoplaston A10, antineoplaston AS2-1 in Prostate Adenocarcinoma (PRAD), sponsored by Burzynski Research Institute. Started Feb 1996; status: terminated.
02
Drugs
antineoplaston A10antineoplaston AS2-1
03
Conditions
Prostate Adenocarcinoma (PRAD)
Beyond the preview
Go deeper on NCT00003533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003533.